Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease.

Journal of neurology, neurosurgery, and psychiatry - 1 Nov 2023

Su Wei-Ming, Gu Xiao-Jing, Dou Meng, Duan Qing-Qing, Jiang Zheng, Yin Kang-Fu, Cai Wei-Chen, Cao Bei, Wang Yi, Chen Yong-Ping

Abstract excerpt

BACKGROUND: Alzheimer's disease (AD) is the leading cause of dementia. Currently, there are no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been widely used to repurpose licensed drugs and discover novel therapeutic targets. Thus, we aimed to identify novel therapeutic targets for AD and analyse their pathophysiological mechanisms and potential side effects. METHODS: A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Brain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Associations and Epidemiology

Share to Genome-Wide Association Study

Share to Hippocampus

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Share to Serpins

Source

Open in PubMed Open full text

Identifiers

PMID: 37349091
DOI: 10.1136/jnnp-2023-331142
PMCID: PMC10579488

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease.PMID 37349091Read ↗

Combining genetics with real-world patient data enables ancestry-specific target identification and drug discovery in Alzheimer’s diseaseSemantic proximity Read ↗

Mendelian Randomization Identified CHRNE as a Potential Drug Target for Alzheimer’s diseaseSemantic proximity Read ↗

Identification of potential drug targets for Alzheimer's disease from genetic insights: A Mendelian randomization study.Semantic proximity Read ↗

Identification of novel drug targets for Alzheimer's disease by integrating genetics and proteomes from brain and blood.Semantic proximity Read ↗

Identification of causally linked blood biomarkers for Alzheimer's disease via reverse transcriptome-wide Mendelian randomization.Semantic proximity Read ↗

Angiotensin-converting enzyme inhibition and Alzheimer’s disease: Findings from proteome-wide Mendelian randomization and a large prospective cohort studySemantic proximity Read ↗

Exploring biomarkers of Alzheimer's disease based on multi-omics and Mendelian randomisation analysis.Semantic proximity Read ↗

The causes and consequences of Alzheimer's disease: phenome-wide evidence from Mendelian randomization.Semantic proximity Read ↗

Therapeutic targets for Alzheimer's disease: Proteome-wide Mendelian randomization and colocalization analysesSemantic proximity Read ↗

APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses.Semantic proximity Read ↗

Pharmacogenomics for the treatment of dementia.Semantic proximity Read ↗

Functional Genetic Biomarkers of Alzheimer’s Disease and Gene Expression from Peripheral BloodSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.